Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496921 | 0.91 | SLC6A2 (0.66) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL30953189 | 0.88 | SLC6A2 (0.73) | SLC6A2OPRM1RENANPEPLNPEP | |
| SCHEMBL29713420 | 0.87 | SLC6A2 (0.62) | SLC6A2OPRM1OPRD1REN | |
| SCHEMBL31257016 | 0.86 | SLC6A2 (0.61) | SLC6A2OPRM1OPRD1RENANPEP | |
| SCHEMBL29591343 | 0.86 | SLC6A2 (0.63) | SLC6A2OPRM1OPRD1ANPEPLNPEP | |
| SCHEMBL30209473 | 0.86 | SLC6A2 (0.61) | SLC6A2OPRM1 | |
| SCHEMBL31676579 | 0.86 | OPRM1 (0.63) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL31059337 | 0.85 | SLC6A2 (0.59) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL30424040 | 0.85 | SLC6A2 (0.62) | SLC6A2OPRM1OPRD1REN | |
| SCHEMBL29571797 | 0.85 | OPRM1 (0.74) | SLC6A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-20260062413-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260015420-A1 | CD47 BINDING AGENTS | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4228623-B1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12448375-B2 | Kinase inhibitors for the treatment of neurodegenerative diseases | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-12421310-B2 | CD47 binding agents | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-09-23 | — | — | US | disclosed |
| US-12383738-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2025-08-12 | — | — | US | disclosed |
| EP-4582452-A1 | NOVEL ANTI-PD-L1 CHIMERIC ANTIGEN RECEPTOR, AND IMMUNE CELLS EXPRESSING SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-20250001166-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-01-02 | — | — | US | disclosed |
| WO-2024049161-A1 | NOVEL ANTI-PD-L1 CHIMERIC ANTIGEN RECEPTOR, AND IMMUNE CELLS EXPRESSING SAME | 한국생명공학연구원 | 2024-03-07 | — | — | WO | disclosed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4228623-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Ohio State Innovation Foundation (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-112979812-B | An isolated binding protein comprising an SCCA antigen binding domain | 东莞市朋志生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220340568-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION | 2022-10-27 | — | — | US | disclosed |
| EP-4010326-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Ohio State Innovation Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022081552-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11291286-B2 | Cosmetic compositions with a micro-mesh structure | ELC MANAGEMENT LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448375-B2 | Kinase inhibitors for the treatment of neurodegenerative diseases | BRDT, BRD3, BRD1 | SLC6A2 4684/4885OPRM1 4443/4885OPRD1 3952/4885 |
| US-20260062413-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BRD3, SMN1; SMN2, HDAC1 | SLC6A2 4551/4885OPRM1 3283/4885OPRD1 2504/4885 |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | CD44, FCGR3B, FCGR2A | SLC6A2 1606/4885OPRM1 2021/4885OPRD1 2255/4885 |
| US-20220340568-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BRDT, BRD3, BRD2 | SLC6A2 4703/4885OPRM1 4432/4885OPRD1 3987/4885 |
| US-20260015420-A1 | CD47 BINDING AGENTS | CD47, FCGR2A, FCGR3B | SLC6A2 3002/4885OPRM1 3641/4885OPRD1 1344/4885 |
| US-11291286-B2 | Cosmetic compositions with a micro-mesh structure | CD44, CUTA, MSH6 | SLC6A2 2777/4885OPRM1 224/4885OPRD1 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.